Kemp Dolliver

Stock Analyst at Brookline Capital

(0.64)
# 4,123
Out of 5,149 analysts
19
Total ratings
38.46%
Success rate
-13.97%
Average return

Stocks Rated by Kemp Dolliver

Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $4.31
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.15
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $5.12
Upside: +232.03%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.87
Upside: +269.99%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.69
Upside: +33.83%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.57
Upside: +2,200.32%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.42
Upside: +7,347.82%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $78.84
Upside: +26.84%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $4.35
Upside: +1,210.34%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.58
Upside: +868.99%
Initiates: Buy
Price Target: $19
Current: $7.61
Upside: +146.39%
Assumes: Buy
Price Target: $8
Current: $0.75
Upside: +964.11%
Initiates: Buy
Price Target: $5.65
Current: $0.61
Upside: +824.26%